Immunome, Inc. (NASDAQ:IMNM) Receives $23.33 Average Target Price from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.33.

IMNM has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $21.00 target price (down previously from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price for the company. Stephens reissued an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Lake Street Capital initiated coverage on Immunome in a report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 target price for the company.

Insider Activity at Immunome

In other Immunome news, Director Jean Jacques Bienaime purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, June 3rd. The shares were acquired at an average cost of $9.38 per share, with a total value of $46,900.00. Following the completion of the acquisition, the director now directly owns 36,415 shares in the company, valued at $341,572.70. The trade was a 15.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. raised its holdings in Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after acquiring an additional 2,054,640 shares during the period. Redmile Group LLC increased its holdings in shares of Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock worth $36,081,000 after purchasing an additional 533,161 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock worth $28,987,000 after purchasing an additional 1,303,753 shares during the last quarter. EcoR1 Capital LLC increased its holdings in shares of Immunome by 5.2% in the first quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock worth $27,454,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Enavate Sciences GP LLC bought a new stake in shares of Immunome in the fourth quarter worth about $36,939,000. 44.58% of the stock is owned by institutional investors.

Immunome Price Performance

IMNM opened at $8.68 on Thursday. The business has a 50 day simple moving average of $8.58 and a two-hundred day simple moving average of $9.22. The firm has a market capitalization of $755.25 million, a price-to-earnings ratio of -2.73 and a beta of 1.94. Immunome has a one year low of $5.15 and a one year high of $16.81.

Immunome (NASDAQ:IMNM) last announced its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. As a group, sell-side analysts expect that Immunome will post -2.21 EPS for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.